This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Protect Patients

Years and Older with Shingrix

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

In those 50 years and older, only SHINGRIX delivered >90% efficacy regardless of age.1,*

We’re working hard to meet the unprecedented demand for SHINGRIX

See the Supply Update

  •   *Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials from subjects who received 2 doses of SHINGRIX (N=7344 and 8250, respectively) or placebo (N=7415 and 8346, respectively) and did not develop a confirmed case of herpes zoster within 1 month after the second dose. See study designs on Efficacy page for more details.1

Start here.

The page links below may be of special interest to you and your team.
Thank you for doing your part to help prevent shingles in your appropriate patients.

Patient Counseling

Talk to your patients about what to expect, including common adverse reactions.

Storage & Dosing

Learn how to store SHINGRIX and about the importance of proper dosing.

Check out the video below featuring reconstitution instructions for SHINGRIX

Learn how to store SHINGRIX and about the importance of proper dosing. Be sure to schedule a second dose for your patients, anytime between 2 and 6 months after the first dose.1

Only SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.1,*

Learn about the results of two phase 3 clinical trials in which adverse reactions to SHINGRIX were studied. 

CDC Recommendations

CDC states that SHINGRIX is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years.2

CDC=Centers for Disease Control and Prevention.

You may also be interested in:

Our library of resources includes handouts for patients, plus pocket and reference guides for you and your staff. 

Watch a range of informative videos, including highlights of pivotal trials and MOA and reconstitution videos.

Get product coding and coverage details for commercial medical benefit and Medicare Part D insurance.

References: 1. Prescribing Information for SHINGRIX. 2. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Trademarks are property of their respective owners.